Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Ryan Swanson, Director, Process Development, Lifecore Biomedical

How Do CDMOs Scale High-Concentration Biologic Formulations?

ByRyan Swanson,Zachary Zubulake

August 21st 2026

Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia recieved accelerated approval from the FDA.

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

ByZachary Zubulake

August 20th 2026

Pasatru (garetosmab-grts) has been approved by the FDA to treat symptoms of fibrodysplasia ossificans progressiva

How a 63-Patient Trial Delivered an FDA Approval

ByZachary Zubulake

August 20th 2026

Ask the Expert: Complying with Standards

BySusan J. Schniepp,Siegfried Schmitt,Susan Haigney

August 20th 2026

FDA concept | Concept of the Food and Drug Administration. Magnifier glass, folder and clock | Image Credit © Sviatlana - stock.adobe.com

What Does Overton's FDA Nomination Mean for Drug Reviews?

ByZachary Zubulake

August 19th 2026

Measuring and Removing Genotoxic Impurities

Articles in this issue

Related Content

How Do CDMOs Scale High-Concentration Biologic Formulations?

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

How a 63-Patient Trial Delivered an FDA Approval

Ask the Expert: Complying with Standards

What Does Overton's FDA Nomination Mean for Drug Reviews?

Trending on Pharmaceutical Technology

Ask the Expert: Complying with Standards

How the Nitrosamine Guidance Shift is Changing LC-MS Workflows for APIs and Peptides

Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models

How Do CDMOs Scale High-Concentration Biologic Formulations?

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing